Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1065
- Registration Number
- NCT00171340
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
🇹🇭Ratchathew, Khonkaen, Thailand
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 143
- Registration Number
- NCT00171925
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 527
- Registration Number
- NCT00171314
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Spain
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 233
- Registration Number
- NCT00171301
- Locations
- 🇸🇾
Novartis Investigative Site, Damascus, Syrian Arab Republic
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 506
- Registration Number
- NCT00171210
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Octreotide Efficacy and Safety in First-line Acromegalic Patients
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00171886
- Locations
- 🇪🇸
Novartis Investigative site, Tarragona, Spain
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00172003
- Locations
- 🇩🇪
Novartis investigative Site, Offenbach, Germany
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00170794
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 437
- Registration Number
- NCT00172042
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, United Kingdom
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT00171704
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath